ABSTRACT
Cyclosporine A(CsA) is the immunosuppressor most frequently used in
transplant surgery and in the treatment of autoimmune diseases. The aim of this study
was to evaluate the hepatorenal toxicity of cyclosporine and the protective effect of
lacidipine (third-generation calcium antagonist, produce a sustained reduction in •
elevated BP). 40 adult albino rats were used in this study. They were divided into four
equal groups. The first group acted as control. The second group received lacidipine
(1mg/kg/daily) orally by gavage for 14 days. CsA was, given to the third and fourth
groups of animals (50mg/kg/daily) orally for 14 days. The fourth group received
lacidipine (1mg/kg/daily) orally, 3 days before and 14 days concurrently with GSA.
Cyclosporine induced hepatorenal toxicity in the form of very highly signcant
increase (P < 0.0005) in both liver and kidney function tests as well as marked
histological changes. Administration of lacidipine with CsA showed very highly
significant decrease (P < 0.0005) •in CsA induced hepatorenal toxicity. Thus we
recommend the use of lacidipine in patients suffering from autoimmune disease and
patients subjected to organs transplantation in order to protect them against CsA
induced hepatorenal toxicity.
1
1 |
